Human IGFBP-6 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF876

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
AF876
AF876-SP
Print Quote
Bulk Order
Conjugate
Catalog #
Biotin
BAF876
View Product
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Neutralization, Western Blot

Cited:

Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

View all IGFBP-6 Antibodies »

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IGFBP-6
Ala25-Gly240
Accession # NP_002169

Specificity

Detects human IGFBP‑6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 30% cross‑reactivity with recombinant mouse IGFBP-6 is observed, 5% cross‑reactivity with recombinant human (rh) IGFBP-2 is observed and less than 1% cross‑reactivity with rhIGFBP-1, rhIGFBP-3, rhIGFBP-4, and rhIGFBP-5 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human IGFBP-6 Antibody

IGFBP‑6 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑6 Antibody.

IGFBP‑6 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑6 Antibody.

Recombinant Human IGFBP-6 (Catalog # 876-B6) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-6 (0.8 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IGFBP-6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF876). The ND50 is typically 8-24 µg/mL.

Applications for Human IGFBP-6 Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human IGFBP-6 (Catalog # 876-B6)

Neutralization

Measured by its ability to neutralize IGFBP‑6 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 8‑24 µg/mL in the presence of 0.8 µg/mL Recombinant Human IGFBP‑6 and 14 ng/mL Recombinant Human IGF‑II.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 2 reviews rated 2 using AF876 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-6

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-6 cDNA encodes a 240 amino acid (aa) residue precursor protein with a putative 24 aa residue signal peptide that is processed to generate the 216 aa residue mature protein that is O-glycosylated. IGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. IGFBP‑6 is found predominantly in CSF and serum. IGFBP-6 binds preferentially to IGF-II, exhibiting a 2-fold higher affinity for IGF-II than for IGF-I.

References

  1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
  2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Long Name

Insulin-like Growth Factor Binding Protein 6

Alternate Names

IGFBP6

Entrez Gene IDs

3489 (Human); 16012 (Mouse)

Gene Symbol

IGFBP6

UniProt

NP_002169

Additional IGFBP-6 Products

Product Documents for Human IGFBP-6 Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human IGFBP-6 Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.